HCA-MAD DUR Board Meeting Agenda to follow

Attendees:
Date: Tuesday, January 14th, 2025
Time: 3:00 PM - 4:00 PM
Remote: Microsoft Teams

Join the meeting now
Meeting ID: 243 592 911 684
Passcode: LSKtjs

Attendees:

Board members:

Mary Jo Zunic, PharmD
Caroline Bonham, MD
Jeremy Snyder, MD
Greg D'Amour, PharmD
Amy Bachyrycz, PharmD

HCA representatives:

Keenan Ryan, PharmD, MPH
Diana Moya, RPh, MHA
Ashley Pugh, RN

Conduent Representation:

Amy Cully, PharmD
Phuonglinh Morsches, PharmD
Lorin Meskin
Brad Stevens

MCO Guests:

Ankit Patel, PharmD, Blue Cross Blue Shield of New Mexico
Samanth Paustian, PharmD, Blue Cross Blue Shield of New Mexico
Laura Schwartz, PharmD, Molina Healthcare of New Mexico
Kendra Ward, PharmD, Presbyterian Health Plan
Frank Koronkiewicz, RPh, MHA, United Healthcare Community Plan of New Mexico

Guests:

Rhonda Clark
Mark Geis
Kim Grennberg
Lindsey Buck
Lori Howarth
Mandeep Sohal
Sara Stolfus

Agenda Item	Leader
Introductions	K. Ryan
Approval of Agenda Agenda approved with additions	K. Ryan
Conflict of Interest/Confidentiality Statements	K. Ryan
Approval of November Minutes	K. Ryan
State Updates • NM FFS/MCO Client Counts and Pharmacy FFS- maintained after COVID, evening out MCO- Presbyterian in the 350k range - Blue Cross next -Molina and then United Total around 670K served Clients went down slightly to around 12% from 14% 578 Pharmacies enrolled, more claims from the last time but less pharmacies enrolled Brand v Generic – generic use should be around 87% Try to bring us back into alignment with 87% generic use	L. Meskin
PRODUR Beg Oct-End of Dec Prenatals outside of age range 4202 will deny for drugs being used on members who are pregnant and drug is contraindicated	L. Morsches
Recent interventions • SMART Newsletter (FY24 Q4) • RSV Newsletter (FY24 Q4) Two mailings went out to around 1,600 providers	A. Cully
Outcome Reports • Hepatitis C Intervention – 1 patient started treatment with an added cost Need more time to see the medical costs as it was too new Q: Is the cost justified for the results? Yes, depending on the intervention and the outcome's goals	A. Cully
Summary reports • Underutilization of SGLT in HF (FY24 Q3) 6 responses as of 1/1/25	B. Cully
Quarterly reports • Metabolic Monitoring of SGAs in Youth • Opioid and SMR Overlap Report	A. Cully

• Opioid and Gabapentinoids Overlap Report • Opioid and Benzodiazepine Overlap Report • Opioid and Antipsychotic Overlap Report • Opioid, Antipsychotics, and Benzodiazepines Overlap Report • Opioid and Non-BZD Sedatives Overlap Report • Opioid-Stimulants Overlap Report Data from the last year Moving from January to December, data is consistent	
Upcoming interventions • Humira First quarter of this year Humira has been identified as a high expense for NM 15 patients identified Letter includes information on the drug itself-precautions, doses, etc Biosimilar information as well Approved to be mailed as Q1 intervention	A. Cully
Open Comment Any edits to last month's quarter? No Approved and will be posted on website Enrollment glitch that led to providers being dis-enrolled- providers need to check their credentials to make sure they are updated Prior authorization and health organization bill- haven't made it far enough in the pre-file system HB 33- Bill removed prior authorizations – autoimmune and cancer Health oversight bill- unevaluated so far What additional data/what needs can be met? -Meaningful interventions with significant responses (higher response rates) target for future conversations	K. Ryan
Adjournment Next meeting April 15th @ 3:00 Adjourned at 3:51	K. Ryan